Remove Life Sciences Remove Pharmaceuticals Remove Primary Care Remove Telemedicine
article thumbnail

Healthcare & Life Science M&A Activity Plummets 1H’22

HIT Consultant

What You Should Know: – The index of Healthcare & Life Science equities tracked by Stout was down 16.8% – Healthcare & Life Science M&A activity plummeted to 338 deals in Q2 2022 versus 535 in Q2 2021 and a record 565 deals in Q4 2021. The proposed changes would reduce the conversion factor by 4.4%

article thumbnail

Enabling better health care, everywhere – my conversation with Microsoft

Health Populi

Molly and I then segued into how the health system incumbent players — hospitals, plans, clinicians, and life science companies — can (and should be) part of the telehealth ecosystem and solutions to deliver care, everywhere.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why #CES2022 Will Be Keynoted By A Health Care Innovator for the First Time

Health Populi

That a pharmaceutical company executive is speaking on the main stage at CES speaks to digital health’s mainstreaming beyond elite athletes and smartwatches that track activity.

article thumbnail

Our Homes as HealthQuarters – Finding Health and Well-Being at CES 2023

Health Populi

You might not think about pharmaceutical companies showing off technology at the “Consumer” Electronics Show, but the pharma industry has had a growing presence at CES for the past few years. Last year, Abbott made a big splash with the company’s Board Chairman/CEO delivering a keynote addressing connected care.